WGU D344 PMHNP Objective Assessment OA Actual Exam
2026/2027 – Complete Q&A with Detailed Rationales | 100%
Verified | Pass Guaranteed – A+ Graded
Section A: Neurobiology, Pathophysiology, & Psychopharmacology (12
Questions)
Q1: A 28-year-old patient with major depressive disorder is started on sertraline 50 mg
daily. The PMHNP explains that the therapeutic effect may take 2-4 weeks to emerge.
Which neurobiological mechanism primarily explains this delayed onset?
A. Immediate increase in serotonin synthesis
B. Gradual downregulation of 5-HT1A autoreceptors and enhanced neuroplasticity
[CORRECT]
C. Gradual downregulation of 5-HT1A autoreceptors and enhanced neuroplasticity
[CORRECT]
D. Rapid depletion of norepinephrine stores
Correct Answer: C
Rationale: The delayed antidepressant effect is attributed to adaptive neuroplastic
changes, including downregulation of somatodendritic 5-HT1A autoreceptors, enhanced
BDNF expression, and increased neurogenesis—not immediate receptor effects. Option
A describes an acute pharmacodynamic effect. Option D is inconsistent with SSRI
mechanism.
,Q2: A patient on clozapine develops fever, sore throat, and fatigue. Laboratory studies
reveal an absolute neutrophil count (ANC) of 800/mm³. Which action is most
appropriate?
A. Continue clozapine and monitor weekly
B. Discontinue clozapine immediately and initiate neutropenia monitoring per REMS
[CORRECT]
C. Discontinue clozapine immediately and initiate neutropenia monitoring per REMS
[CORRECT]
D. Reduce clozapine dose by 50%
Correct Answer: C
Rationale: ANC 800/mm³ indicates moderate neutropenia (ANC 500-1000). Per the
Clozapine REMS, clozapine must be immediately discontinued, and the patient
monitored until ANC recovers. Option A is dangerous. Option D is inappropriate—dose
reduction does not address agranulocytosis risk.
Q3: A patient with bipolar disorder on lithium presents with coarse tremor, ataxia,
confusion, and diarrhea. The serum lithium level is 2.2 mEq/L. Which condition does
this represent?
A. Therapeutic lithium level with benign side effects
B. Lithium toxicity [CORRECT]
C. Lithium toxicity [CORRECT]
D. Neuroleptic malignant syndrome
,Correct Answer: C
Rationale: Lithium toxicity is diagnosed at levels >1.5 mEq/L (severe >2.0 mEq/L),
presenting with coarse tremor, ataxia, confusion, GI symptoms, and potential
seizures/renal failure. The therapeutic range is 0.6-1.2 mEq/L. Option A dangerously
misinterprets the level. Option D presents with rigidity and elevated CK, not primarily GI
symptoms.
Q4: Which CYP450 enzyme is primarily responsible for metabolizing risperidone to its
active metabolite 9-hydroxyrisperidone (paliperidone)?
A. CYP1A2
B. CYP2D6 [CORRECT]
C. CYP2D6 [CORRECT]
D. CYP3A4
Correct Answer: C
Rationale: Risperidone is primarily metabolized by CYP2D6 to 9-hydroxyrisperidone
(paliperidone). Genetic polymorphisms in CYP2D6 can significantly affect risperidone
plasma levels. Option A metabolizes clozapine and olanzapine. Option D metabolizes
quetiapine and ziprasidone.
Q5: A patient with treatment-resistant depression is started on a transdermal selegiline
patch. Which dietary restriction is necessary?
A. No restrictions with the transdermal formulation at 6 mg/24 hours
B. Tyramine restriction is required at all doses [CORRECT]
, C. Tyramine restriction is required at all doses [CORRECT]
D. Only avoid aged cheeses
Correct Answer: C
Rationale: While the 6 mg/24 hour transdermal selegiline patch has reduced dietary
tyramine restrictions compared to oral MAOIs, higher doses (9-12 mg) require tyramine
restriction. Additionally, all MAOIs carry risk of serotonin syndrome with serotonergic
agents. Option A is overly permissive.
Q6: Which antipsychotic carries the highest risk of QTc prolongation and requires
baseline ECG monitoring?
A. Aripiprazole
B. Ziprasidone [CORRECT]
C. Ziprasidone [CORRECT]
D. Olanzapine
Correct Answer: C
Rationale: Ziprasidone carries the highest risk of QTc prolongation among atypical
antipsychotics and requires baseline and follow-up ECG monitoring. Aripiprazole
(Option A) has minimal QTc effect. Olanzapine (Option D) primarily carries metabolic
risks.
Q7: A patient with ADHD is started on atomoxetine. Which monitoring is required due to
the FDA black box warning?
2026/2027 – Complete Q&A with Detailed Rationales | 100%
Verified | Pass Guaranteed – A+ Graded
Section A: Neurobiology, Pathophysiology, & Psychopharmacology (12
Questions)
Q1: A 28-year-old patient with major depressive disorder is started on sertraline 50 mg
daily. The PMHNP explains that the therapeutic effect may take 2-4 weeks to emerge.
Which neurobiological mechanism primarily explains this delayed onset?
A. Immediate increase in serotonin synthesis
B. Gradual downregulation of 5-HT1A autoreceptors and enhanced neuroplasticity
[CORRECT]
C. Gradual downregulation of 5-HT1A autoreceptors and enhanced neuroplasticity
[CORRECT]
D. Rapid depletion of norepinephrine stores
Correct Answer: C
Rationale: The delayed antidepressant effect is attributed to adaptive neuroplastic
changes, including downregulation of somatodendritic 5-HT1A autoreceptors, enhanced
BDNF expression, and increased neurogenesis—not immediate receptor effects. Option
A describes an acute pharmacodynamic effect. Option D is inconsistent with SSRI
mechanism.
,Q2: A patient on clozapine develops fever, sore throat, and fatigue. Laboratory studies
reveal an absolute neutrophil count (ANC) of 800/mm³. Which action is most
appropriate?
A. Continue clozapine and monitor weekly
B. Discontinue clozapine immediately and initiate neutropenia monitoring per REMS
[CORRECT]
C. Discontinue clozapine immediately and initiate neutropenia monitoring per REMS
[CORRECT]
D. Reduce clozapine dose by 50%
Correct Answer: C
Rationale: ANC 800/mm³ indicates moderate neutropenia (ANC 500-1000). Per the
Clozapine REMS, clozapine must be immediately discontinued, and the patient
monitored until ANC recovers. Option A is dangerous. Option D is inappropriate—dose
reduction does not address agranulocytosis risk.
Q3: A patient with bipolar disorder on lithium presents with coarse tremor, ataxia,
confusion, and diarrhea. The serum lithium level is 2.2 mEq/L. Which condition does
this represent?
A. Therapeutic lithium level with benign side effects
B. Lithium toxicity [CORRECT]
C. Lithium toxicity [CORRECT]
D. Neuroleptic malignant syndrome
,Correct Answer: C
Rationale: Lithium toxicity is diagnosed at levels >1.5 mEq/L (severe >2.0 mEq/L),
presenting with coarse tremor, ataxia, confusion, GI symptoms, and potential
seizures/renal failure. The therapeutic range is 0.6-1.2 mEq/L. Option A dangerously
misinterprets the level. Option D presents with rigidity and elevated CK, not primarily GI
symptoms.
Q4: Which CYP450 enzyme is primarily responsible for metabolizing risperidone to its
active metabolite 9-hydroxyrisperidone (paliperidone)?
A. CYP1A2
B. CYP2D6 [CORRECT]
C. CYP2D6 [CORRECT]
D. CYP3A4
Correct Answer: C
Rationale: Risperidone is primarily metabolized by CYP2D6 to 9-hydroxyrisperidone
(paliperidone). Genetic polymorphisms in CYP2D6 can significantly affect risperidone
plasma levels. Option A metabolizes clozapine and olanzapine. Option D metabolizes
quetiapine and ziprasidone.
Q5: A patient with treatment-resistant depression is started on a transdermal selegiline
patch. Which dietary restriction is necessary?
A. No restrictions with the transdermal formulation at 6 mg/24 hours
B. Tyramine restriction is required at all doses [CORRECT]
, C. Tyramine restriction is required at all doses [CORRECT]
D. Only avoid aged cheeses
Correct Answer: C
Rationale: While the 6 mg/24 hour transdermal selegiline patch has reduced dietary
tyramine restrictions compared to oral MAOIs, higher doses (9-12 mg) require tyramine
restriction. Additionally, all MAOIs carry risk of serotonin syndrome with serotonergic
agents. Option A is overly permissive.
Q6: Which antipsychotic carries the highest risk of QTc prolongation and requires
baseline ECG monitoring?
A. Aripiprazole
B. Ziprasidone [CORRECT]
C. Ziprasidone [CORRECT]
D. Olanzapine
Correct Answer: C
Rationale: Ziprasidone carries the highest risk of QTc prolongation among atypical
antipsychotics and requires baseline and follow-up ECG monitoring. Aripiprazole
(Option A) has minimal QTc effect. Olanzapine (Option D) primarily carries metabolic
risks.
Q7: A patient with ADHD is started on atomoxetine. Which monitoring is required due to
the FDA black box warning?
